British Biotech

Last updated

British Biotech plc
(LSE:BBG Nasdaq:BBIOY)
Industry Biotechnology
Founded1986
Defunct2003
FateMerged
Successor Vernalis plc
Headquarters Oxford, United Kingdom
Key people
CEO
Keith McCullagh, 1986–1998
Elliot Goldstein, 1998–2002
Tim Edwards, 2002–2003
Chair
Brian Richards, 1986–1998
Christopher Hampson, 1998–2002
Peter Fellner, 2002–2003
Number of employees
500

British Biotech was a British-based biotechnology company founded as British Biotechnology Limited in 1986 by former G D Searle managers Keith McCullagh and Brian Richards. [1] It was the first British biotech company to be publicly listed when it was floated on 1 July 1992. [2]

Contents

Controversy

In 1996, despite having no compounds on or near the market, the company was temporarily valued at nearly $2.5 billion, [3] largely on the basis of its two main development drugs: marimastat (a novel matrix metalloprotease inhibitor for cancer treatment [4] ) and lexipafant (Zacutex, for pancreatitis). Batimastat (codename BB94) progressed as far as stage 3 in its clinical trial, although not orally bioavailable, there are other methods of administration, including transdermal.

In February 1998, Dr Andrew Millar was dismissed as Head of Clinical Research and went on to make allegations that "the Board were running a business plan consistent only with extreme and unfounded optimism". [5] These events were the subject of an inquiry by the House of Commons Select Committee on Science and Technology in August 1998 which absolved Dr Millar of any responsibility for the company's problems. [5]

Subsequent investigations by the Securities and Exchange Commission, Food and Drug Administration, London Stock Exchange and the European Medicines Evaluation Agency found that British Biotech had wilfully misled the public about the progress of marimastat [6] and that unblinding data before the end of clinical trials does not necessarily invalidate the results. [7] Marimastat underwent Phase III trials in collaboration with Schering-Plough Corporation. [8] Further development of Zacutex was abandoned due to poor clinical trial results. [9]

The corporate politics behind the downfall of British Biotech was later recorded for a BBC2 Series Blood on the Carpet. [10]

Disappearance

In 2003, British Biotech merged with RiboTargets and then into Vernalis Group. The British Biotech company name disappeared after this merger and remaining staff integrated into the new Vernalis plc organisation in Winnersh, Berkshire.

Related Research Articles

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

<span class="mw-page-title-main">Labcorp Drug Development</span>

Labcorp Drug Development is a contract research organization headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is part of Labcorp, which employs more than 70,000 people worldwide.

<span class="mw-page-title-main">Pharmacia & Upjohn</span> Global pharmaceutical company

Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.

Takeda Oncology is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.

Sir Christopher Thomas Evans is a Welsh professor, scientist and biotechnology entrepreneur. Evans is known for founding and co-founding numerous successful biotech companies in the United Kingdom.

<span class="mw-page-title-main">Marimastat</span> Chemical compound

Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.

<span class="mw-page-title-main">Basilea Pharmaceutica</span> Swiss pharmaceutical company

Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.

<span class="mw-page-title-main">Batimastat</span> Chemical compound

Batimastat is a drug that was invented by Laurie Hines of British Biotech. It is an antimetastatic drug that belongs to the family of drugs called angiogenesis inhibitors. It acts as a matrix metalloproteinase inhibitor (MMPI) by mimicking natural MMPI peptides. Dan Lednicer wrote about this compound in book #6 of his organic drug synthesis series.

<span class="mw-page-title-main">ARIAD Pharmaceuticals</span> Defunct oncology company

ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients.

<span class="mw-page-title-main">Cellectis</span> French biopharmaceutical company

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

<span class="mw-page-title-main">Zymeworks</span>

ZymeworksInc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.

<span class="mw-page-title-main">Geoffrey von Maltzahn</span> American inventor

Geoffrey von Maltzahn is an American biological engineer and businessman in the biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health, Generate Biomedicines and Tessera Therapeutics. He has over 200 bioengineering and biotechnology patents and applications.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

Moderna, Inc. is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Calico Life Sciences LLC is a subsidiary of Alphabet Inc. with a focus on biotechnology. Calico's goal is to increase the understanding of the biology that controls human aging, attempting to devise interventions that may enable people to lead longer and healthier lives.

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

<span class="mw-page-title-main">Ionis Pharmaceuticals</span> Biotechnology company

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.

Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.

<span class="mw-page-title-main">Peter Elliott (pharmacologist)</span> British pharmacologist (born 1958)

Peter Elliott is a British pharmacologist and drug developer who has initiated clinical trials across a range of disease areas, and is the co-developer of Velcade, a drug used to treat multiple myeloma.

References

  1. ↑ Rosen, Michael S. (2003). "The Final Death Knell of Chicago's G.D. Searle". Midwest Business. Archived from the original on 27 September 2007. Retrieved 12 May 2003.
  2. ↑ "BBIOY IPO". IPO Summary Report. NEA. 1 December 1992. Archived from the original on 28 September 2007. Retrieved 1 August 2006.
  3. ↑ Hodgson, John (2006). "Ten years of biotech gaffes". Nature Biotechnology. Nature Publishing Group. 24 (3): 270–273. doi:10.1038/nbt0306-270. PMID   16525384. S2CID   560311 . Retrieved 8 March 2006.
  4. ↑ Wojtowicz-Praga S; Torri J; Johnson M; Steen V; Marshall J; Ness E; Dickson R; Sale M; Rasmussen HS; Chiodo TA; Hawkins MJ (1998). "Phase I trial of Marimastat". Journal of Clinical Oncology. American Society of Clinical Oncology. Archived from the original on 12 May 2005.
  5. 1 2 "Fifth Report". Select Committee on Science and Technology. House of Commons. 1998.
  6. ↑ "British Biotech settles up". Nature Biotechnology . Nature Publishing Group. 1999.
  7. ↑ Khan, Alex (1999). "Shedding Biotech's Bad Name". IP/IT Update. NIPC. Archived from the original on 27 October 2006.
  8. ↑ "Marimastat Update". BusinessWire. 2001.
  9. ↑ "Zacutex UK Phase III clinical data presented at American Gastroenterological Association". Select Committee on Science and Technology. House of Commons. 1998.
  10. ↑ "BBC2's Blood on the Carpet". BBC. 2001.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.